Thrombin or factor Xa inhibitors

A compound selected from the group:

• or a stereoisomer or pharmaceutically acceptable salt thereof, wherein;
• G is selected from the group:
• Ln is a linker which is absent or is selected from CH2, *CH2NHC(O)*CH(Ra)NHC(O) *CH2NHC(O)CH2, and *CH(Ra)NHC(O)CH2 and the * indicates where Ln is bonded to G;
• M1 is absent;
• Ra is selected from C(O)C(O)OR3, C(O)C(O)NR2R2a, and C(O)-A;
• R is selected from H, Cl, F, Br, I, (CH2)tOR3, C1-4 alkyl, benzyl, OCF3, CF3, C(O)NR7R8, and (CR8R9)tNR7R8;
• Z is selected from (CR8R9)1-4, (CR8R9)rO(CR8R9)r, (CR8R9)rNR3(CR8R9)r, (CR8R9)rC(O)(CR8R9)r, (CR8R9)rC(O)O(CR8R9)r, (CR8R9)rOC(O)(CR8R9)r, (CR8R9)rC(O)NR3(CR8R9)r, (CR8R9)rNR3C(O)(CR8R9)r, (CR8R9)rOC(O)O(CR8R9)r, (CH2)rOC(O)NR3(CR8R9)r, (CR8R9)rNR3C(O)O(CR8R9)r, (CH2)rNR3C(O)NR3(CR8R9)r, (CR8R9)rS(O)p(CR8R9)r, (CR8R9)rS(O)2(CH═CH), (CCR8R9)rSO2NR3(CR8R9)r, (CR8R9)rNR3SO2(CR8R9)r, and (CR8R9)rNR3SO2NR3(CR8R9)r, provided that Z does not form a N—N, N—O, N—S, NCH2N, NCH2O, or NCH2S bond with the groups to which Z is attached;
• R1′ is selected from H, C1-3 alkyl, F, Cl, Br, I, —CN, —CHO, (CF2)rCF3, (CH2)rOR2, NR2R2a, C(O)R2c, OC(O)R2, (CF2)rCO2R2c, S(O)p(CH2)rR2b, NR2(CH2)rOR2, C(═NR2c)NR2R2a, NR2C(O)R2b, NR2C(O)NHR2b, NR2C(O)2R2a, OC(O)NR2aR2b, C(O)NR2R2a, C(O)NR2(CH2)rOR2, SO2NR2R2a, NR2SO2R2b, C3-6 carbocyclic residue substituted with 0-2 R4, and 5-10 membered heterocyclic ring containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R4, provided that when R4 is substituted with R1′ then R1′ is other than N(CH2)2(CH2)tR1′, O(CH2)2(CH2)tR1′, and S(CH2)2(CH2)tR1′;
• R1″ is selected from H, CH(CH2OR2)2, C(O)R2c, C(O)NR2R2a, S(O)R2b, S(O)2R2b, and SO2NR2R2a;
• R2, at each occurrence, is selected from H, CF3, C1-6 alkyl, benzyl, C3-6 carbocyclic residue substituted with 0-2 R4b, and 5-6 membered heterocyclic ring containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R4b;
• R2a, at each occurrence, is selected from H, CF3, C1-6 alkyl, benzyl, C3-6 cycloalkylmethyl substituted with 0-2 R4b, C3-6 carbocyclic residue substituted with 0-2 R4b, and 5-6 membered heterocyclic ring containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R4b;
• R2b, at each occurrence, is selected from CF3, C1-4 alkoxy, C1-6 alkyl, benzyl, C3-6 carbocyclic residue substituted with 0-2 R4b, and 5-6 membered heterocyclic ring containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R4b;
• R2c, at each occurrence, is selected from CF3, OH, C1-4 alkoxy, C1-6 alkyl, benzyl, C3-6 carbocyclic residue substituted with 0-2 R4b, and 5-6 membered heterocyclic ring containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R4b;
• alternatively, R2 and R2a, together with the atom to which they are attached, combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring substituted with 0-2 R4b and containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;
• R3, at each occurrence, is selected from H, C1-4 alkyl, and phenyl;
• R3a, at each occurrence, is selected from H, C1-4 alkyl, and phenyl;
• R3b, at each occurrence, is selected from H, C1-4 alkyl, and phenyl;
• R3c, at each occurrence, is selected from C1-4 alkyl, and phenyl;
• A is selected from:
• C3-10 carbocyclic residue substituted with 0-2 R4, and
• 5-10 membered heterocyclic ring containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R4;
• R4, at each occurrence, is selected from H, ═O, (CH2)rOR2, F, Cl, Br, I, C1-4 alkyl, —CN, NO2, (CH2)rNR2R2a, (CH2)rC(O)R2c, NR2C(O)R2b, C(O)NR2R2a, NR2C(O)NR2R2a, C(═NR2)NR2R2a, C(═NS(O)2R5)NR2R2a, NHC(═NR2)NR2R2a, C(O)NHC(═NR2)NR2R2a, SO2NR2R2a, NR2SO2NR2R2a, NR2SO2—C1-4 alkyl, NR2SO2R5, S(O)pR5, (CF2)rCF3, NHCH2R1″, OCH2R1″, SCH2R1″, N(CH2)2(CH2)tR1′, O(CH2)2(CH2)tR1′, and S(CH2)2(CH2)tR1′;
• alternatively, one R4 is a 5-6 membered aromatic heterocycle containing from 1-4 heteroatoms selected from the group consisting of N, O, and S;
• R4b, at each occurrence, is selected from H, ═O, (CH2)rOR3, F, Cl, Br, I, C1-4 alkyl, —CN, NO2, (CH2)rNR3R3a, (CH2)rC(O)R3, (CH2)rC(O)OR3c, NR3C(O)R3a, C(O)NR3R3a, NR3C(O)NR3R3a, C(═NR3)NR3R3a, NR3C(═NR3)NR3R3a, SO2NR3R3a, NR3SO2NR3R3a, NR3SO2—C1-4 alkyl, NR3SO2CF3, NR3SO2-phenyl, S(O)pCF3, S(O)p—C1-4 alkyl, S(O)p-phenyl, and (CF2)rCF3;
• R5, at each occurrence, is selected from CF3, C1-6 alkyl, phenyl substituted with 0-2 R6, and benzyl substituted with 0-2 R6;
• R6, at each occurrence, is selected from H, OH, (CH2)rOR2, halo, C1-4 alkyl, CN, NO2, (CH2)rNR2R2a,(CH2)rC(O)R2b, NR2C(O)R2b, NR2C(O)NR2R2a, C(═NH)NH2, NHC(═NH)NH2, SO2NR2R2a, NR2SO2NR2R2a, and NR2SO2C1-4 alkyl;
• R7, at each occurrence, is selected from H, OH, C1-6 alkyl, C1-6 alkylcarbonyl, C1-6 alkoxy, C1-4 alkoxycarbonyl, (CH2)n-phenyl, C6-10 aryloxy, C6-10 aryloxycarbonyl, C6-10 arylmethylcarbonyl, C1-4 alkylcarbonyloxy C1-4 alkoxycarbonyl, C6-10 arylcarbonyloxy C1-4 alkoxycarbonyl, C1-6 alkylaminocarbonyl, phenylaminocarbonyl, and phenyl C1-4 alkoxycarbonyl;
• R8, at each occurrence, is selected from H, C1-6 alkyl and (CH2)n-phenyl;
• alternatively, R7 and R8 combine to form a 5 or 6 membered saturated, ring which contains from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;
• R9, at each occurrence, is selected from H, C1-6 alkyl and (CH2)n-phenyl;
• n, at each occurrence, is selected from 0,1, 2, and 3;
• p, at each occurrence, is selected from 0, 1, and 2;
• r, at each occurrence, is selected from 0, 1, 2, and 3;
• and,
• t, at each occurrence, is selected from 0, 1, 2, and 3.